Overview of Jim Simons (Trades, Portfolio)'s Latest Portfolio Addition Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently expanded its investment portfolio with the acquisition of 3,681,125 shares in Vanda Pharmaceuticals Inc (NASDAQ:VNDA). With a trade price of $4.22 per share, the firm has demonstrated a strategic interest in the biopharmaceutical sector, marking a new investment direction with potential growth opportunities.
In its recent review of a district court decision the Federal Circuit characterized as "a thorough opinion," the Federal Circuit affirmed invalidation for obviousness of four claims.
Overview
Vanda Pharmaceuticals Inc. is a leading global
biopharmaceutical company focused on the development and commercialization of
innovative therapies to address high unmet medical needs and. | May 3, 2023
/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended.
Vanda’s trial results of HETLIOZ (tasimelteon) for insomnia suggest that circadian misalignment may be the etiology behind chronic primary insomnia for many patients.